Patients with systemic lupus erythematosus (SLE) who achieved a state of prolonged low disease activity had equivalent long-term outcomes to those who were in sustained clinical remission, Canadian researchers reported.
Among patients who had persistent low disease activity, defined as an SLE Disease Activity Index (SLEDAI) of ≤2, the Systemic Lupus International Collaborating Clinics Damage Index (SLICC/DI) was 1.10 after 10 years, while those with persistent clinical remission, or a SLEDAI of zero, had a mean SLICC/DI of 0.96 at that time point, which was not significantly different (P=0.63), according to Murray B. Urowitz, MD, of the University Health Network in Toronto, and colleagues.
Full article here.
